Tech Transfer Central
Archer Norris

Collaborative Agreements in Life Sciences: Key Considerations

Structuring Terms to Expand Product Lines, Reduce Costs and Risks, and Leverage and Protect Assets
Published by Strafford Publications, Inc.
Format: On-Demand or DVD
Originally presented: January 26, 2012

Twitter Facebook Linkedin Pinterest Email
Price: $297 + S&H
order button
Please note: You will be taken to the Strafford website to complete your order.

This CLE webinar will provide guidance to counsel for companies in the life sciences industry for structuring collaborative agreements. The panel will discuss key considerations including allocation of risk, establishment of milestones and obligations, protection of IP rights, and termination of agreements.


Collaboration agreements can invigorate a life sciences companies’ success. When facing the expiration of key patents, companies can develop new R&D opportunities and resources for final-stage development, clinical trials, manufacturing and distribution of new products through strategic partnerships with others.

While collaborative agreements provide businesses with an avenue to access resources, create new products and bring them to market, reduce expenses, and allocate risk, they must be carefully structured to protect a company’s assets.

Counsel involved in developing collaboration agreements for businesses must understand the critical challenges involved in allocating risks, protecting IP rights and handling termination of agreements.

Listen as our authoritative panel examines the key considerations when structuring collaborative agreements, including terms addressing allocation of risk, establishment of party roles, milestones and obligations, protection of IP rights, and termination of agreements, among others. The panel will outline approaches and best practices for structuring the collaboration agreements for life science companies.


  • Key considerations
  • Contract terms
    1. Risk allocation
    2. Roles of parties
    3. Establishing milestones
    4. Party obligations
    5. Development and marketing
    6. IP rights
    7. Termination
    8. Handling of lawsuits
  • Best practices for structuring the agreements


The panel will review these and other key questions:

  • What considerations and potential pitfalls should counsel keep in mind when crafting collaborative agreements?
  • What are the key contract terms that should be included in life sciences collaborative agreements?
  • What approaches are most effective for assigning ownership and development rights?

Following the speaker presentations, you’ll have an opportunity to get answers to your specific questions during the interactive Q&A.


Judith A. Hasko, Partner
Latham & Watkins LLP, Menlo Park, Calif.
She focuses on representing companies developing biotechnology, pharmaceutical, medical device and diagnostic products, and investors in such companies, in technology-based commercial transactions. She advises clients in connection with corporate partnering, joint venture, asset purchase, spin-out, licensing, distribution, manufacturing, co-development, profit-sharing and co-promotion matters.

Amy L. Toro, Partner
Covington & Burling, San Francisco
She specializes in technology transactions, with particular emphasis on life science arrangements, such as collaboration and license agreements. Her clients include pharmaceutical companies, biotechnology clients, and non-profit organizations. She also has experience with advising high technology clients on matters relating to the development and licensing of standardized technologies.

Continuing Legal Education

Continuing Legal Education credits are granted for an additional $65 per person. Please refer to the options on the order page to take advantage of these credits.

order button
Please note: You will be taken to the Strafford
website to complete your order.